The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.

摘要: Belantamab mafodotin (belamaf) is a first-in-class anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) that recently gained regulatory approval for the treatment of relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody (mAb), proteasome inhibitor (PI), and immunomodulatory drug (IMiD). As first BCMA-targeted therapy to be approved in along with its "off-the-shelf" outpatient administration, belamaf addresses significant unmet need RRMM IMiD, PI, mAb therapy, otherwise known as triple-class myeloma. Belamaf also associated frequent corneal ocular adverse events, which represents unique toxicity therapeutics, administration requires multidisciplinary approach oncologists eye care specialists safely effectively manage on therapy. In this review, we discuss preclinical clinical data leading belamaf, monitoring mitigation strategies current future role landscape.